JP2008509950A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509950A5
JP2008509950A5 JP2007526351A JP2007526351A JP2008509950A5 JP 2008509950 A5 JP2008509950 A5 JP 2008509950A5 JP 2007526351 A JP2007526351 A JP 2007526351A JP 2007526351 A JP2007526351 A JP 2007526351A JP 2008509950 A5 JP2008509950 A5 JP 2008509950A5
Authority
JP
Japan
Prior art keywords
phenyl
dioxo
imidazolidin
thiazol
butyramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007526351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509950A (ja
JP4927733B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/008633 external-priority patent/WO2006018188A2/en
Publication of JP2008509950A publication Critical patent/JP2008509950A/ja
Publication of JP2008509950A5 publication Critical patent/JP2008509950A5/ja
Application granted granted Critical
Publication of JP4927733B2 publication Critical patent/JP4927733B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007526351A 2004-08-17 2005-08-09 置換ヒダントイン Expired - Fee Related JP4927733B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US60/602,175 2004-08-17
US68299705P 2005-05-20 2005-05-20
US60/682,997 2005-05-20
PCT/EP2005/008633 WO2006018188A2 (en) 2004-08-17 2005-08-09 Substituted hydantoins

Publications (3)

Publication Number Publication Date
JP2008509950A JP2008509950A (ja) 2008-04-03
JP2008509950A5 true JP2008509950A5 (enExample) 2012-01-05
JP4927733B2 JP4927733B2 (ja) 2012-05-09

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526351A Expired - Fee Related JP4927733B2 (ja) 2004-08-17 2005-08-09 置換ヒダントイン

Country Status (16)

Country Link
US (1) US7427635B2 (enExample)
EP (1) EP1781649B1 (enExample)
JP (1) JP4927733B2 (enExample)
KR (2) KR20090006885A (enExample)
AR (1) AR050297A1 (enExample)
AT (1) ATE404556T1 (enExample)
AU (1) AU2005274390B2 (enExample)
BR (1) BRPI0514515A (enExample)
CA (1) CA2576599A1 (enExample)
DE (1) DE602005008986D1 (enExample)
ES (1) ES2313389T3 (enExample)
MX (1) MX2007001846A (enExample)
PL (1) PL1781649T3 (enExample)
RU (1) RU2383542C2 (enExample)
TW (1) TW200621764A (enExample)
WO (1) WO2006018188A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
CN101778839A (zh) 2007-08-16 2010-07-14 霍夫曼-拉罗奇有限公司 取代的乙内酰脲
WO2009080523A1 (en) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as mek kinase inhibitors
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
DK2303021T3 (en) * 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
TW201113280A (en) * 2009-07-03 2011-04-16 Nensius Res As Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
MX2012012460A (es) 2010-04-28 2012-11-21 Bayer Cropscience Ag Derivados de cetoheteroarilpiperidina y de cetoheteroarilpiperazin a como fungicidas.
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP3853225B1 (en) * 2018-09-17 2023-11-29 Yungjin Pharm. Co., Ltd. N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer
KR20210116325A (ko) * 2020-03-13 2021-09-27 영진약품 주식회사 티아졸 유도체 또는 이의 약제학적으로 허용가능한 염을 포함하는 암의 예방 또는 치료용 약학 조성물
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU757046B2 (en) 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
AU5227001A (en) * 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
WO2003008365A2 (en) * 2001-07-19 2003-01-30 Pharmacia Italia S.P.A. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents

Similar Documents

Publication Publication Date Title
JP5675773B2 (ja) Ccr2の4−アゼチジニル−1−フェニル−シクロヘキサンアンタゴニスト
ES2240558T3 (es) Derivados de tiazol y oxazol como activadores de receptores activados por el proliferador de peroxisoma humano.
JP5244863B2 (ja) ジオキサン−2−アルキルカルバメート誘導体の製造法およびその中間体
RU2383542C2 (ru) Замещенные гидантоины
RU2007116317A (ru) Гексафторизопропанол-замещенные производные простых эфиров
JP2018531982A5 (enExample)
JP2009508963A5 (enExample)
JP2007519692A5 (enExample)
JP4796046B2 (ja) ピペリジニルアルキルカーバメートの誘導体、これらの製造方法及びfaah酵素インヒビターとしての使用
JP2007511485A5 (enExample)
JP2006506380A5 (enExample)
AU2010236336B2 (en) 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2
JP2010504323A5 (enExample)
IL287159B2 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
JP2004507501A5 (enExample)
JP2014523400A5 (enExample)
JP2006525990A5 (enExample)
KR101972619B1 (ko) 페닐 유도체
CA2598516A1 (en) Benzisoxazole derivatives
KR20140117301A (ko) 페닐 유도체를 함유하는 의약
JP2024543451A5 (enExample)
JP2006509022A5 (enExample)
US8440819B2 (en) Therapeutic substituted beta-lactams
RU2006102866A (ru) Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar
JP2007532576A5 (enExample)